Lilly and OpenAI Collaborate on Developing New Treatments for Drug-Resistant Bacteria

Lilly and OpenAI Collaborate on Developing New Treatments for Drug-Resistant Bacteria

By, Admin 27 June 2024

Overview

Eli Lilly and Company (NYSE: LLY) has partnered with OpenAI to leverage OpenAI's generative AI technology for developing new antimicrobial treatments to combat drug-resistant pathogens. Antimicrobial resistance (AMR) is a significant global health threat.

Words from CI&DO: Lilly

Diogo Rau, Executive Vice President and Chief Information and Digital Officer at Lilly, highlighted the collaboration's importance, stating, ""Our partnership with OpenAI represents a significant step in addressing the growing threat of antimicrobial resistance. Generative AI offers a promising approach to accelerate the discovery of novel antimicrobials and develop customized technologies to fight drug-resistant pathogens. This collaboration underscores our commitment to tackling major health challenges worldwide.""

Strata Affected by Lilly

AMR affects countries across different income levels, worsened by socioeconomic factors and the misuse of antimicrobials in humans, animals, and agriculture, posing serious risks to public health.

Statement from OpenAI

OpenAI, expressed enthusiasm for the collaboration, saying, ""We are excited to work with Lilly to advance treatments for microbial infections. Advanced AI has the potential to bring transformative advancements in pharmaceuticals, and we are dedicated to partnering with industry leaders to deliver tangible benefits for patients.""

Lilly & OpenAI Collaboration

  • Lilly's collaboration with OpenAI builds on its existing commitment to combating drug-resistant pathogens through initiatives like the Social Impact Venture Capital Portfolio. 
  • In 2020, Lilly committed $100 million to the AMR Action Fund, aiming to develop two to four new antibiotics by 2030 and strengthen defenses against multi-drug-resistant pathogens. 
  • In April 2023, the AMR Action Fund announced new investments in biotech companies focusing on various infections.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!